Abivax Shares Jump 7.17% Midday, Supported by Entry into Nasdaq Biotechnology Index

Abivax has seen a 7.17% increase midday this Friday, December 19, reaching 104.60 euros, after closing at 97.60 euros the previous day. The stock has thus recovered some of the ground lost over the past seven days, which saw a decline of 9.67%. Trading volumes remain modest with 0.06% of the capital traded, indicating continued caution among operators following recent significant fluctuations. Over three months, the biotech maintains a solid performance of 49.64%, and over the year, the increase reaches 1,298%, making it one of the top performers in the SBF 120. This rebound occurs in a favorable context, fueled by the announcement of its entry into the Nasdaq Biotechnology Index effective before the opening of U.S. markets on Monday, December 22. The company also revealed that 22 scientific abstracts on obefazimod will be presented at the ECCO congress in February 2026, including an oral presentation on preclinical antifibrotic data.

Abivax announced on December 18 its inclusion in the Nasdaq Biotechnology Index, effective before the market opens on Monday, December 22, 2025. Didier Blondel, CFO of Abivax, stated that this entry marks a significant milestone, highlighting the progress made in the development of obefazimod, particularly through the successful phase 3 ABTECT trials in ulcerative colitis. Companies included in this index must meet several eligibility criteria, including minimum market capitalization, average daily transaction volume, and tenure as a listed company. This institutional recognition enhances Abivax's visibility among international investors and reflects growing confidence in the commercial potential of its drug candidate. The integration into the NBI also fits into a positive dynamic marked by a series of target price upgrades by American brokers, including Leerink Partners, Piper Sandler, and Citizens, between December 16 and 17, with targets now ranging between $131 and $142 on the Nasdaq listing.

At 104.60 euros, the price is above the 50-day moving average set at 93.48 euros, confirming the maintenance of a fundamentally bullish trend despite the recent weekly decline. The gap with the 200-day moving average, positioned at 45.26 euros, demonstrates the extent of the revaluation carried out since the beginning of the year. The RSI is at 42, in a slightly oversold neutral zone, suggesting that the stock has absorbed some of the recent volatility without entering critical oversold territory. The MACD shows a negative histogram at -1.43, with a MACD line at 0.80 crossing below the signal line at 2.24, indicating a slowdown in short-term momentum without invalidating the long-term dynamic. The Bollinger Bands frame the stock between a support at 89.90 euros and a resistance at 117.73 euros, with the price currently in the middle part of this channel. With a negative beta of -0.21, Abivax maintains a marked decorrelation with the CAC 40, allowing it to operate independently of the movements of the Paris market.